New Partnership of CELLphenomics and Kyan Therapeutics
This partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry
20-Apr-2023 -
CELLphenomics and KYAN Therapeutics announced their new partnership. By combining KYAN's technology platform, Optim.AI™ - which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics' proprietary PD3D® technology, this partnership aims to offer an efficient ...
artificial intelligence
drug combinations
drug development